Evidence map›Paper›PMID 37558706›Full record

Observational studyBlood cancer journal2023

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.

Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, Leyla O Shune, Joseph P McGuirk, Douglas W Sborov, Charlotte B Wagner, M Hakan Kocoglu, Aaron Rapoport, Shebli Atrash and 19 more

Open access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 6 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 6 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 14 institutions in 1 country.

Christopher J Ferreri *The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2997-4856
Michelle A T Hildebrandt *The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hamza HashmiMedical University of South Carolina, Charleston, SC, USA.
Leyla O ShuneThe University of Kansas Medical Center, Kansas City, KS, USA.
Joseph P McGuirkThe University of Kansas Medical Center, Kansas City, KS, USA.ORCID http://orcid.org/0000-0002-0539-4796
Douglas W SborovThe University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Charlotte B WagnerThe University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-0568-0781
M Hakan KocogluUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Aaron RapoportUniversity of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Shebli AtrashLevine Cancer Institute, Charlotte, NC, USA.
Peter M VoorheesLevine Cancer Institute, Charlotte, NC, USA.
Jack KhouriCleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
Danai DimaCleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
Aimaz AfroughMyeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Gurbakhash KaurMyeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Larry D AndersonMyeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-6531-9595
Gary SimmonsVirginia Commonwealth University Massey Cancer Center, Richmond, VA, USA.
James A DavisMedical University of South Carolina, Charleston, SC, USA.ORCID http://orcid.org/0000-0001-7978-1652
Nilesh KalariyaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren C PeresH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-6620-8600
Yi LinMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1556-6416
Murali JanakiramCity of Hope, Duarte, CA, USA.
Omar NadeemDana-Farber Cancer Institute, Boston, MA, USA.
Melissa AlsinaH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Frederick L LockeH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Surbhi SidanaStanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3288-7614
Doris K Hansen *H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Krina K Patel *The University of Texas MD Anderson Cancer Center, Houston, TX, USA. KPatel1@mdanderson.org.ORCID http://orcid.org/0000-0002-8894-027X
Omar Alexis Castaneda Puglianini *H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-0423-5870
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USSouthwestern Medical CenterCleveland Clinic · USLevine Cancer Institute · USMedical University of South Carolina · USUniversity of Kansas Medical Center · USUniversity of Maryland, Baltimore · USUniversity of Utah · USCity of Hope · USDana-Farber Cancer Institute · USMayo Clinic in Arizona · USStanford University · USVirginia Commonwealth University · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.

Indexed as

B-Cell Maturation AntigenImmunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeB-Cell Maturation Antigenidecabtagene vicleucelReceptors, Chimeric Antigen

Identifiers

PMID37558706
PMCPMC10412575
OpenAlexW4385707936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.